CBIS IN THE NEWS.
Excerpt: "Cannabis Science has reported that their groundbreaking laboratory research with Dana-Farber Cancer Institute using Nanoparticle Drone technology and Cannabinoids to successfully kill cancer cells has now reached a serious level of attention. The Cannabis Science, Dana-Farber research team has now begun next level planning to bring this efficacious research to full commercialization."
Excerpt: "Cannabis Science, a U.S. company specializing in the development of cannabinoid-based medications, announces a collaborative research agreement with Dana Farber/Harvard Cancer Center (DF/HCC). The agreement lays the foundation for a cooperative research initiative to explore and develop new cannabinoid medicines to fight cancer. This agreement is also the first step in the development of clinical trials that will lead to approval of successful cannabinoids by the FDA."
Excerpt: "Wilfred Ngwa, Ph.D., Harvard Director of Global Health Catalyst at the Dana Farber/Harvard Cancer Center (DF/HCC), has recently commended Cannabis Science Inc for its presentation to the Harvard Medical School. 'Partnership between the Cannabis Science team and scientists here at the DF/HCC are expected to bring a deeper understanding of the potential effectiveness of cannabinoids in the treatment of cancer and other chronic diseases,' elaborated Ngwa."
Excerpt: “My work as a member of the Scientific Advisory Board of Cannabis Science, a publicly traded company researching and commercializing medicinal cannabinoids, enables me to see the research and understand the promise of medicinal cannabinoids. That’s why I support their legitimate, medically valid use.”
Excerpt: “Cannabis Science is exploring the use of cannabinoids to treat Kaposi’s sarcoma in people with HIV as well as a potential therapy directed at inhibiting the HIV protein Tat, which is key for viral replication and modulates the expression of genes that regulate a variety of cellular activities. This would be revolutionary for people living with HIV, as chemotherapy, a primary treatment for Kaposi’s sarcoma, is largely unavailable in Africa, which has the highest burden of the disease. A cannabinoid-based antiviral would be cheaper than currently available drugs, greatly decreasing the cost of treating HIV and allowing for increased access to treatment for the nearly 7 million HIV patients around the world who need antiretroviral drugs but do not currently have access to them.”
Excerpt: “When asked of the potential for cannabinoids to be used as treatments for diseases such as HIV, Dr. Bob Melamede, president and director of Cannabis Science, stated: 'If people are able to objectively look at the medical research on cannabis, there would likely be no debate regarding the widespread need for cannabis-based medicines.' ”
Excerpt: “Melamede, who teaches at the University of Colorado at Colorado Springs… is both a scholar and a patient on the state's registry, and he says the drug has the potential to benefit almost everyone: stroke patients, cancer patients, the mentally ill and possibly even soldiers exposed to chemical warfare.”
Excerpt: “While the National Institute of Health at one point noted that cannabis had a possible therapeutic effect on cancer, for the most part cancer patients using cannabis do so without the blessing of official medical science. Theirs is the science of the underground, of anecdote, of stories told by the cured, of explanations offered by doctors willing to step outside the mainstream, and of scientists like Melamede.”
Excerpt: “The inevitable reemergence of the virus in the cooler weather that it enjoys is further complicated by the likelihood that the world's vaccine producers will not have an adequate supply of vaccinations in time for the initial return of the virus. Unlike other seasonal influenza strains, the H1N1 swine flu virus has remained active throughout the warmer spring and summer months…With this backdrop in mind, one CEO has an alternative and controversial idea.”
Excerpt: “Dr. Melamede from the University of Colorado, Colorado Springs, USA, writes that although cannabis smoke and tobacco smoke are chemically very similar, evidence suggests that their effects are very different and that cannabis smoke is less carcinogenic than tobacco smoke.”
Excerpt: “Many veterans and others are using cannabis medically to treat the symptoms of Post-Traumatic Stress Disorder (PTSD), according to preliminary results of a new survey. Cannabis Science Inc., which describes itself as 'an emerging pharmaceutical cannabis company,' is reviewing the interim results of its survey of more than 1,400 people.”
Excerpt: "This summer, IBX Bio Inc. has joined forces with Cannabis Science (CBIS) for an FDA-approved clinical trial. The studies will research the applications of the combination of GenePro® and CS-TATI-1, a cannabinoid-based drug. The collaboration is historic, maximizing the synergistic effects of cannabinoids and advanced HIV immunotherapy."
